Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
261
-
262
-
263
-
264
Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
Published 2012“…<div><h3>Background</h3><p>The Step trial raised the possibility that uncircumcised men with pre-existing Ad5 neutralizing antibodies carried an increased risk of HIV infection after vaccination. …”
-
265
-
266
-
267
-
268
-
269
-
270
-
271
Differentially regulated genes in cells with increased or decreased expression of miR-106a-5p.
Published 2013“…(C) A Venn diagram of the overlap of altered genes with increased or decreased miR-106a-5p expression. …”
-
272
-
273
Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability.
Published 2015“…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”
-
274
Laquinimod prevents EAE and decreases encephalitogenicity of T cells.
Published 2012“…Representative FACS staining is shown including quantification (n = 4–5 mice per group). (E) Laquinimod decreases pathogenic potential of T cells. …”
-
275
-
276
-
277
-
278
-
279
B2 decreases glycolytic intermediates in cells.
Published 2025“…<b>(C)</b> Heatmap of targeted metabolomic data. Each column is a separate biological replicate (n = 5). The box indicates the clustering of decreased downstream glycolytic intermediates in B2-treated cells. …”
-
280